Cooper Consumer Health Acquires Viatris' Over-the-Counter Business
July 3, 2024
Cooper Consumer Health has completed the acquisition of the Over-the-Counter (OTC) business of Viatris Inc., following regulatory approvals and worker council consultations. The deal brings more than 200 brands (including Betadine, Saugella, Armolipid and CB12), two manufacturing sites in Mérignac (France) and Confienza (Italy) and an R&D centre in Monza (Italy) into Cooper's platform, doubling Cooper's revenues to approximately €1.2bn.
- Buyers
- Cooper Consumer Health
- Targets
- Viatris Inc. Over-the-Counter (OTC) business
- Sellers
- Viatris Inc.
- Industry
- Pharmaceuticals
- Location
- Pennsylvania, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Viatris to Acquire Pacira BioSciences for $1.65 Billion
October 8, 2026
Pharmaceuticals
Viatris agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, valuing the company at approximately $1.65 billion. The acquisition will add Pacira’s non-opioid pain therapies, including EXPAREL and ZILRETTA, to Viatris’ portfolio and is expected to close by the end of 2026, subject to customary conditions.
-
Merck to Acquire Verona Pharma for Approximately $10 Billion
July 9, 2025
Pharmaceuticals
Merck, through a subsidiary, entered into a definitive agreement to acquire Verona Pharma in a transaction valued at approximately $10 billion (at $107 per ADS). The acquisition is intended to add Ohtuvayre (ensifentrine) to Merck’s cardio-pulmonary pipeline, following FDA approval for COPD in June 2024.
-
Avista Healthcare Partners Acquires Trillium Health Care Products
August 7, 2024
Pharmaceuticals
Avista Healthcare Partners has completed the acquisition of Trillium Health Care Products, a Brockville, Ontario-based CDMO specializing in branded over‑the‑counter (OTC) products, from New Water Capital. Avista plans to invest in Trillium’s growth, expand its footprint and capabilities, and use the business as a consumer‑healthcare platform for potential strategic add‑on acquisitions.
-
Norwell Consumer Healthcare Acquires Boyd Pharmaceuticals' Canadian OTC Brands
July 5, 2023
Pharmaceuticals
Norwell Consumer Healthcare Inc. has entered a definitive agreement to acquire a portfolio of assets from Boyd Pharmaceuticals, including the Colace, Colace Glycerin, Dequadin, Allenburys and Gelusil brands in Canada. The asset purchase strengthens Norwell's gastroenterology and cough & cold portfolio and supports accelerated growth of its consumer OTC business.
-
Carlin Consumer Health Acquires Zegerid OTC from Bayer
February 1, 2022
Pharmaceuticals
Hildred Capital, Bourne Partners Strategic Capital and The Emerson Group launched Carlin Consumer Health and acquired the Zegerid OTC brand from Bayer AG to establish a consumer health/OTC platform. The investors plan to invest in marketing, sales and product development to grow the Zegerid brand across U.S. retail channels; financial terms were not disclosed.
-
Cooper-Vemedia (Charterhouse) Acquires 12-Brand OTC Portfolio from Sanofi
April 16, 2018
Pharmaceuticals
Charterhouse-backed Cooper-Vemedia has acquired a portfolio of 12 over-the-counter (OTC) pharmaceutical brands from Sanofi for €158 million. The brands—spanning dermatology, well-being, eye care and other categories—are predominantly sold in France and Italy and will be integrated into Cooper-Vemedia’s pan‑European OTC platform to strengthen its product offering and market position.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.